Related references
Note: Only part of the references are listed.The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
John Mascarenhas et al.
BLOOD ADVANCES (2022)
Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
A-Jin Lee et al.
BLOOD RESEARCH (2021)
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Ayalew Tefferi et al.
LEUKEMIA (2021)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
TARGET-Seq: A Protocol for High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing
Alba Rodriguez-Meira et al.
STAR PROTOCOLS (2020)
A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
Mary Frances McMullin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
Ruben Mesa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Ruben A. Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Claire N. Harrison et al.
BLOOD (2017)
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Alessandro Maria Vannucchi et al.
ANNALS OF HEMATOLOGY (2017)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis
N. Pemmaraju et al.
LEUKEMIA (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Share Paper
